<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Biodesix Announces Receipt of CLIA Registration Number

    October 31, 2008

    Biodesix, Inc., is pleased to announce receipt of a CLIA registration which allows the company to commercially market Veristrat® .

    Biodesix Announces VeriStrat® Data in Head and Neck Cancer to be Presented at ASCO

    May 14, 2009

    Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University will be presenting data on Veristrat at the 45th Annual Meeting of ASCO.

    Biodesix Names Paul J Beresford, Formerly of Roche Diagnostics, as Vice President, Business Development and Stategic Marketing

    December 5, 2008

    Biodesix announced that Paul J. Beresford has joined the Company as Vice President, Business Development and Strategic Marketing.

    Biodesix Names Douglas E. Swan, formerly of Imclone Systems Incorporated, as Vice President, Commercial Operations

    October 1, 2008

    Biodesix announced today that Douglas E. Swan has joined the company as Vice President, Commercial Operations, reporting directly to David Brunel, CEO

    Biodesix Announces Issuance of Key Patent for Serum Test that Identifies Lung Cancer Patients Likely to Benefit from Targeted Therapy

    June 21, 2010

    Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.

    Biodesix Advances the Field of Personalized Medicine with the Launch of VeriStrat®

    May 5, 2009

    Biodesix announces the U.S. commercial availability of VeriStrat.

    Biodesix to Present at 2011 Biotech Showcase

    January 7, 2011

    Biodesix's Paul Beresford will present at the 2011 Biotech Showcase conference taking place January 10–12th at the Parc 55 Wyndham in San Francisco, CA

    Biodesix CEO to Present at Personalized Medicine Partnerships Conference

    February 5, 2010

    Biodesix's CEO, David Brunel, will present at the 2010 Personalized Medicine Partnerships conference, Wednesday, February 24th, at 11:00 a.m. eastern time.

    Biodesix Secures $10 Million in Series B-1 Funding

    September 28, 2009

    Biodesix announced today that it has completed $10 million in Series B-1 financing round. The financing was led by existing shareholders and board members.

    Biodesix Completes Series C Financing and Receives Grant

    November 5, 2010

    Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.
    1 2 3